Dexamethasone-loaded cochlear implants: How to provide a desired "burst release".
Burst release
Cochlear implant
Dexamethasone
Dexamethasone phosphate
Silicone
Journal
International journal of pharmaceutics: X
ISSN: 2590-1567
Titre abrégé: Int J Pharm X
Pays: Netherlands
ID NLM: 101753452
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
23
01
2021
revised:
03
06
2021
accepted:
06
06
2021
entrez:
23
9
2021
pubmed:
24
9
2021
medline:
24
9
2021
Statut:
epublish
Résumé
Cochlear implants containing iridium platinum electrodes are used to transmit electrical signals into the inner ear of patients suffering from severe or profound deafness without valuable benefit from conventional hearing aids. However, their placement is invasive and can cause trauma as well as local inflammation, harming remaining hair cells or other inner ear cells. As foreign bodies, the implants also induce fibrosis, resulting in a less efficient conduction of the electrical signals and, thus, potentially decreased system performance. To overcome these obstacles, dexamethasone has recently been embedded in this type of implants: into the silicone matrices separating the metal electrodes (to avoid short circuits). It has been shown that the resulting drug release can be controlled over several years. Importantly, the dexamethasone does not only act against the immediate consequences of trauma, inflammation and fibrosis, it can also be expected to be beneficial for remaining hair cells in the long term. However, the reported amounts of drug released at "early" time points (during the first days/weeks) are relatively low and the in vivo efficacy in animal models was reported to be non-optimal. The aim of this study was to increase the initial "burst release" from the implants, adding a freely water-soluble salt of a phosphate ester of dexamethasone. The idea was to facilitate water penetration into the highly hydrophobic system and, thus, to promote drug dissolution and diffusion. This approach was efficient: Adding up to 10% dexamethasone sodium phosphate to the silicone matrices substantially increased the resulting drug release rate at early time points. This can be expected to improve drug action and implant functionality. But at elevated dexamethasone sodium phosphate loadings device
Identifiants
pubmed: 34553137
doi: 10.1016/j.ijpx.2021.100088
pii: S2590-1567(21)00017-7
pmc: PMC8441626
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100088Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
One of the authors is the Editor-in-Chief of this journal. The manuscript has been subject to all of the journal's usual procedures, including peer review, which has been handled independently of the Editor-in-Chief.
Références
Hear Res. 2018 Oct;368:49-66
pubmed: 29576310
Int J Pharm X. 2019 May 21;1:100015
pubmed: 31517280
Otolaryngol Head Neck Surg. 2020 Oct;163(4):791-798
pubmed: 32484378
Cochlear Implants Int. 2013 Jan;14(1):45-50
pubmed: 22333428
J Control Release. 2012 Apr 10;159(1):60-8
pubmed: 22233971
Int J Pharm. 2021 Jan 5;592:120038
pubmed: 33159985
Eur Arch Otorhinolaryngol. 2016 Jul;273(7):1745-53
pubmed: 26319276
HNO. 2017 Jan;65(Suppl 1):19-28
pubmed: 27933352
Laryngoscope Investig Otolaryngol. 2019 Dec 11;5(1):122-131
pubmed: 32128438
Otol Neurotol. 2014 Aug;35(7):1168-71
pubmed: 24841917
Drug Discov Today. 2005 Oct 1;10(19):1299-306
pubmed: 16214674
PLoS One. 2016 Feb 03;11(2):e0147552
pubmed: 26840740
Curr Opin Otolaryngol Head Neck Surg. 2019 Oct;27(5):381-386
pubmed: 31460985
Hear Res. 2016 Jun;336:44-52
pubmed: 27109196
Pacing Clin Electrophysiol. 1996 Jul;19(7):1016-20
pubmed: 8823826
Eur J Pharm Sci. 2016 Mar 31;85:31-8
pubmed: 26826281
Hear Res. 2004 Oct;196(1-2):58-68
pubmed: 15464302
Hear Res. 2015 Sep;327:89-101
pubmed: 25987502
Eur J Pharm Sci. 2019 Jan 1;126:23-32
pubmed: 29723597
Otol Neurotol. 2015 Sep;36(9):1572-9
pubmed: 26375981
Drug Dev Ind Pharm. 2018 Jan;44(1):89-98
pubmed: 28851247
J Control Release. 2014 Jan 28;174:171-6
pubmed: 24291333
Int J Pharm. 2015 Oct 15;494(1):83-101
pubmed: 26260230
J Control Release. 2016 Mar 28;226:248-57
pubmed: 26860286
Neuroscience. 2016 Mar 1;316:261-78
pubmed: 26718602
Int J Pharm. 2017 Jun 30;526(1-2):280-290
pubmed: 28487190
Audiol Neurootol. 2009;14(6):350-60
pubmed: 19923805
Acta Otolaryngol. 1986 Mar-Apr;101(3-4):161-4
pubmed: 3518332
PLoS One. 2014 Oct 20;9(10):e110238
pubmed: 25329543
Cochlear Implants Int. 2015 Jul;16(4):195-200
pubmed: 24593762
Audiol Neurootol. 2011;16(1):1-11
pubmed: 20431286
Acta Otolaryngol Suppl. 1988;458:79-83
pubmed: 3245438
Int J Pharm. 2021 Feb 1;594:120180
pubmed: 33338566
Otol Neurotol. 2018 Aug;39(7):803-815
pubmed: 29995001
J Biomed Mater Res B Appl Biomater. 2010 Aug;94(2):388-98
pubmed: 20583307
Int J Pharm. 2015 Jun 20;487(1-2):187-96
pubmed: 25882015
Eur J Pharm Sci. 2019 Jan 1;126:82-92
pubmed: 29792920
Int J Pharm. 2016 Jul 25;509(1-2):85-94
pubmed: 27050866
Drug Deliv Transl Res. 2021 Feb;11(1):214-226
pubmed: 32488817
Adv Drug Deliv Rev. 2008 Dec 14;60(15):1583-99
pubmed: 18848590
Int J Pharm. 2014 Aug 25;471(1-2):297-302
pubmed: 24907595
Hear Res. 2016 Jul;337:12-24
pubmed: 26892906